THALED CAPSULES Specified Drug Use-results Survey (Crow-Fukase (POEMS) syndrome: Long-term Use)

THALED CAPSULES Specified Drug Use-results Survey (Crow-Fukase (POEMS) syndrome: Long-term Use) - THALED CAPSULES Specified Drug Use-results Survey (Crow-Fukase (POEMS) syndrome: Long-term Use)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043600

Enrollment

100

Registered

2021-03-15

Start date

2021-02-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crow-Fukase (POEMS) syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with POEMS syndrome who will receive the treatment with THALED CAPSULES

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety (adverse drug reactions)	—

Secondary

Measure	Time frame
Efficacy (Serum VEGF reduction rate, modified Rankin Scale, Overall Neuropathy Limitation Scale, PFS, OS)	—

Countries

Japan

Contacts

Public ContactMasanao Nakatani

Fujimoto Pharmaceutical Corporation Department of Pharmacovigilance

pms@fujimoto-pharm.co.jp072-332-5151

Outcome results